138 related articles for article (PubMed ID: 35166474)
1. [Morphological characteristics of renal changes in Fabry disease].
Lerner YV; Tsoy LV; Grishina AN; Varshavsky VA
Arkh Patol; 2022; 84(1):21-26. PubMed ID: 35166474
[TBL] [Abstract][Full Text] [Related]
2. First phenotypic description of a female patient with c.610 T > C variant of GLA: a renal-predominant presentation of Fabry disease.
Greillier S; Daniel L; Caillaud C; Dussol B; Touchard G; Goujon JM; Jourde-Chiche N; Bobot M
BMC Med Genet; 2020 Jun; 21(1):137. PubMed ID: 32590976
[TBL] [Abstract][Full Text] [Related]
3. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
4. A case of latent heterozygous Fabry disease in a female living kidney donor candidate.
Minami M; Mizuma E; Nakahara M; Oda Y; Yoshimine H; Tokunaga K; Mitsuke A; Yamada Y; Enokida H; Masutani K; Goto N; Ido A
CEN Case Rep; 2021 Feb; 10(1):30-34. PubMed ID: 32712909
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: renal biopsy-proven cases from China.
Zhang SH; Liu ZH; Zeng CH; Li SJ; Chen HP; Su J; Li LS
J Nephrol; 2007; 20(6):716-26. PubMed ID: 18046674
[TBL] [Abstract][Full Text] [Related]
6. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
[TBL] [Abstract][Full Text] [Related]
7. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: a morphologic study of 11 cases.
Fischer EG; Moore MJ; Lager DJ
Mod Pathol; 2006 Oct; 19(10):1295-301. PubMed ID: 16799480
[TBL] [Abstract][Full Text] [Related]
9. Evolution of renal pathology in Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Nebuloni M; Tosoni A; Vago GL;
Acta Paediatr Suppl; 2003 Dec; 92(443):6-8; discussion 5. PubMed ID: 14989458
[TBL] [Abstract][Full Text] [Related]
10. Hemizygous Fabry disease associated with IgA nephropathy: a case report.
Shimohata H; Yoh K; Takada K; Tanaka H; Usui J; Hirayama K; Kobayashi M; Yamagata K
J Nephrol; 2009; 22(5):682-4. PubMed ID: 19810002
[TBL] [Abstract][Full Text] [Related]
11. Hemizygous Fabry disease associated with membranous nephropathy: A rare case report
.
Zhou W; Ni Z; Zhang M
Clin Nephrol; 2018 Sep; 90(3):227-231. PubMed ID: 29792392
[TBL] [Abstract][Full Text] [Related]
12. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.
Mauer M; Glynn E; Svarstad E; Tøndel C; Gubler MC; West M; Sokolovskiy A; Whitley C; Najafian B
PLoS One; 2014; 9(11):e112188. PubMed ID: 25386848
[TBL] [Abstract][Full Text] [Related]
13. A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.
Veloso VSP; Ataides TL; Canziani MEF; Veloso MP; da Silva NA; Barreto DV; Pereira ERS; de Moura LAR; Barreto FC
Nephron; 2018; 138(2):147-156. PubMed ID: 28892806
[TBL] [Abstract][Full Text] [Related]
14. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
[TBL] [Abstract][Full Text] [Related]
15. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
16. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
17. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes.
Jehn U; Bayraktar S; Pollmann S; Van Marck V; Weide T; Pavenstädt H; Brand E; Lenders M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768768
[TBL] [Abstract][Full Text] [Related]
18. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
19. A case of minimal change disease in a Fabry patient.
Zarate YA; Patterson L; Yin H; Hopkin RJ
Pediatr Nephrol; 2010 Mar; 25(3):553-6. PubMed ID: 19876652
[TBL] [Abstract][Full Text] [Related]
20. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
